Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements

Launched by CHINESE UNIVERSITY OF HONG KONG · May 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a hormone called Anti-Müllerian Hormone (AMH) and how it relates to conditions like Polycystic Ovarian Syndrome (PCOS) and Premature Ovarian Insufficiency (POI), which can affect women's fertility. The researchers want to understand how measuring AMH levels can help diagnose PCOS, manage POI, and improve outcomes for women undergoing fertility treatments. They will also explore how AMH levels relate to other important factors in fertility, such as egg quality and the chances of a successful pregnancy.

Women aged between 36 and 52 who are being treated for PCOS or POI at specific clinics in Hong Kong may be eligible to participate. Participants will have their AMH levels monitored and may receive guidance on fertility treatments based on their results. It’s important to note that women under 10 or over 45, or those with certain hormonal disorders, will not be included in the study. If you or someone you know is facing these issues, this trial could offer valuable insights into improving fertility treatment options.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI
• • Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment
• Exclusion Criteria:
• • Women with age \<10 or ≥45
• • Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion